Beihai Gofar Chuanshan Biological Co., Ltd.
600538.SS · SHH
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -2.31 | 0.09 | 0.29 | 1.36 |
| FCF Yield | -0.30% | -1.17% | -0.99% | -0.94% |
| EV / EBITDA | -36.17 | -42.44 | 50.89 | 95.09 |
| Quality | ||||
| ROIC | -11.10% | -8.67% | 3.77% | 1.03% |
| Gross Margin | 25.63% | 24.30% | 27.56% | 25.79% |
| Cash Conversion Ratio | -0.02 | 0.22 | -0.45 | -0.60 |
| Growth | ||||
| Revenue 3-Year CAGR | -9.52% | -4.57% | 19.75% | 7,516,704.14% |
| Free Cash Flow Growth | 71.00% | -19.11% | 20.67% | -216.43% |
| Safety | ||||
| Net Debt / EBITDA | 1.51 | 2.63 | -3.59 | -5.86 |
| Interest Coverage | -37.03 | -172.20 | 75.76 | 21.18 |
| Efficiency | ||||
| Inventory Turnover | 3.05 | 3.49 | 3.90 | 4.31 |
| Cash Conversion Cycle | 289.60 | 278.72 | 237.37 | 204.15 |